AZNAstraZenecaRunning, no new patients
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 30 (final count)
- Started
- Sep 24, 2024
- Main results expected
- May 4, 2026
- Fully finished
- Mar 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS) at 12 months
Measured over: From date of first dose until 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06606847 · record last updated 2026-05-15 · checked 2026-11-09 15:47 UTC